IS4384A - Ensím latar - Google Patents

Ensím latar

Info

Publication number: IS4384A
Authority: IS; Iceland
Prior art keywords: protecting group; lazy; enzymes; amidino; intermediates
Prior art date: 1994-06-15

Application number

IS4384A

Other languages

English (en)

Inventor

Francis Hodson Harold

Martin John Palmer Richard

Alan Sawyer David

Graham Knowles Richard

Witold Franzmann Karl

James Drysdale Martin

Ifeyinwa Davies Patricia

Alicia Rebecca Clark Helen

George Shearer Barry

Smith Steven

Original Assignee

The Wellcome Foundation Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-15

Filing date

1996-11-13

Publication date

1996-11-13

1995-05-15 Priority claimed from GBGB9509774.7A external-priority patent/GB9509774D0/en

1996-11-13 Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited

1996-11-13 Publication of IS4384A publication Critical patent/IS4384A/is

Links

102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
239000000543 intermediate Substances 0.000 abstract 2
125000006239 protecting group Chemical group 0.000 abstract 2
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 abstract 1
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
DFEXVBOMMIJOAW-UHFFFAOYSA-N carbamimidoylsulfonylmethanimidamide Chemical class NC(=N)S(=O)(=O)C(N)=N DFEXVBOMMIJOAW-UHFFFAOYSA-N 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)

IS4384A 1994-06-15 1996-11-13 Ensím latar IS4384A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP94304314		1994-06-15
GBGB9509774.7A GB9509774D0 (en)	1995-05-15	1995-05-15	Enzyme inhibitors
PCT/GB1995/001378 WO1995034534A1 (en)	1994-06-15	1995-06-14	Enzyme inhibitors

Publications (1)

Publication Number	Publication Date
IS4384A true IS4384A (is)	1996-11-13

Family

ID=26137155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4384A IS4384A (is)	1994-06-15	1996-11-13	Ensím latar

Country Status (28)

Country	Link
US (2)	USRE39576E1 (is)
EP (2)	EP0765308B1 (is)
JP (2)	JP2989010B2 (is)
KR (1)	KR100430207B1 (is)
CN (1)	CN1070849C (is)
AT (2)	ATE229001T1 (is)
AU (1)	AU692892B2 (is)
BR (1)	BR9507995A (is)
CA (1)	CA2192668A1 (is)
CY (2)	CY2238B1 (is)
DE (2)	DE69529101T2 (is)
DK (2)	DK0957087T3 (is)
ES (2)	ES2189322T3 (is)
FI (1)	FI965019A7 (is)
GR (1)	GR3033746T3 (is)
HU (1)	HUT77407A (is)
IL (2)	IL114142A (is)
IS (1)	IS4384A (is)
MX (1)	MX9606136A (is)
MY (1)	MY115437A (is)
NO (1)	NO308655B1 (is)
NZ (1)	NZ289157A (is)
PT (2)	PT765308E (is)
RU (1)	RU2162841C2 (is)
SI (2)	SI0765308T1 (is)
TW (1)	TW442453B (is)
WO (1)	WO1995034534A1 (is)
ZA (1)	ZA954940B (is)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2740339B1 (fr) *	1995-10-26	1997-12-05	Oreal	Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
US6620848B2 (en)	1997-01-13	2003-09-16	Smithkline Beecham Corporation	Nitric oxide synthase inhibitors
US6369272B1 (en)	1997-01-13	2002-04-09	Glaxosmithkline	Nitric oxide synthase inhibitors
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
AU6139798A (en) *	1997-02-04	1998-08-25	General Hospital Corporation, The	A novel method for treating epidermal or dermal conditions
AU8647198A (en) *	1997-08-12	1999-03-01	Chugai Seiyaku Kabushiki Kaisha	Remedies for diseases associated with bone resorption
EP1415982A1 (en) *	1998-03-11	2004-05-06	G.D. SEARLE & CO.	Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
US6284735B1 (en) *	1998-04-28	2001-09-04	Lion Bioscience Ag	HP-3228 and related peptides to treat sexual dysfunction
US6534503B1 (en)	1998-04-28	2003-03-18	Lion Bioscience Ag	Melanocortin receptor-3 ligands to treat sexual dysfunction
EP1076649A4 (en)	1998-04-28	2010-06-02	Trega Biosciences Inc	ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
WO2001005401A1 (en) *	1999-07-16	2001-01-25	Trega Biosciences, Inc.	Melanocortin receptor-3 ligands to treat sexual dysfunction
GEP20094625B (en) *	2000-03-24	2009-03-10	Pharmacia Corp	Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
AR034120A1 (es) *	2000-04-13	2004-02-04	Pharmacia Corp	Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
GB0031179D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
DE10111049A1 (de) *	2001-03-06	2002-09-12	Beiersdorf Ag	Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111050A1 (de) *	2001-03-06	2002-09-12	Beiersdorf Ag	Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
DE10111054A1 (de) *	2001-03-06	2002-09-12	Beiersdorf Ag	Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10111052A1 (de) *	2001-03-06	2002-09-12	Beiersdorf Ag	Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
US7012098B2 (en) *	2001-03-23	2006-03-14	Pharmacia Corporation	Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
BR0310061A (pt) *	2002-05-16	2005-03-01	Pharmacia Corp	Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
GB0214147D0 (en) *	2002-06-19	2002-07-31	Glaxo Group Ltd	Formulations
ATE509909T1 (de) *	2003-03-11	2011-06-15	Pharmacia Corp	S-ä2-ä(i-iminoethyl)aminoüethylü-2-methyl-l- cystein-maleat-hydrochlorid krystallinischer salz
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
EP1687308B1 (en) *	2003-11-17	2019-06-12	Merck & Cie	Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
GB0418045D0 (en)	2004-08-12	2004-09-15	Glaxo Group Ltd	Compounds
EP1841780B1 (en)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
MY145343A (en)	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
PE20061193A1 (es)	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
DE102005047946A1 (de) *	2005-10-06	2007-05-03	Bayer Healthcare Ag	Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
PE20071068A1 (es)	2005-12-20	2007-12-13	Glaxo Group Ltd	Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
MX2008013411A (es)	2006-04-20	2008-11-04	Glaxo Group Ltd	Nuevos compuestos.
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
PL2046787T3 (pl)	2006-08-01	2011-10-31	Glaxo Group Ltd	Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
WO2008147445A2 (en) *	2006-11-09	2008-12-04	University Of Maryland, Baltimore	Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
MX2010012814A (es)	2008-05-23	2010-12-20	Amira Pharmaceuticals Inc	Inhibidor de proteina activadora de 5-lipoxigenasa.
US8163743B2 (en)	2008-06-05	2012-04-24	GlaxoGroupLimited	4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
ES2383246T3 (es)	2008-06-05	2012-06-19	Glaxo Group Limited	4-amino-indazoles
WO2010094643A1 (en)	2009-02-17	2010-08-26	Glaxo Group Limited	Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja)	2009-03-09	2015-01-21	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
EP2408769A1 (en)	2009-03-17	2012-01-25	Glaxo Group Limited	Pyrimidine derivatives used as itk inhibitors
EP2408916A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120029054A1 (en)	2009-03-19	2012-02-02	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408458A1 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411018A2 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111497A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411520A2 (en)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2421834A1 (en)	2009-04-24	2012-02-29	Glaxo Group Limited	Pyrazole and triazole carboxamides as crac channel inhibitors
AR076373A1 (es)	2009-04-24	2011-06-08	Glaxo Group Ltd	N-pirazolil carboxamidas como inhibidores de canales de calcio
LT2899191T (lt)	2009-04-30	2017-10-25	Glaxo Group Limited	Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
MX337575B (es) *	2009-10-09	2016-03-10	Zafgen Corp	Compuestos de sulfona y métodos para lafabricación y uso de éstos.
WO2011067365A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Novel compounds
JP2013512880A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
EP3020393B1 (en)	2009-12-16	2020-10-07	3M Innovative Properties Company	Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
RS54286B1 (sr)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US9326987B2 (en)	2010-09-08	2016-05-03	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
EP2630127A1 (en)	2010-10-21	2013-08-28	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
US9156791B2 (en)	2010-10-21	2015-10-13	Glaxo Group Limited	Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
EP2683716A1 (en)	2011-03-11	2014-01-15	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
KR20160060100A (ko)	2013-09-22	2016-05-27	칼리토르 사이언시즈, 엘엘씨	치환된 아미노피리미딘 화합물 및 이용 방법
WO2015148867A1 (en)	2014-03-28	2015-10-01	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
US20170100385A1 (en)	2014-05-12	2017-04-13	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions comprising danirixin for treating infectious diseases
GB201512635D0 (en)	2015-07-17	2015-08-26	Ucl Business Plc	Uses of therapeutic compounds
JP2018527362A (ja)	2015-09-11	2018-09-20	サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅＬａｋｅＰｈａｒｍａＣｏ．，Ｌｔｄ．	置換されたヘテロアリール化合物および使用方法
WO2019099311A1 (en)	2017-11-19	2019-05-23	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
KR102737185B1 (ko)	2018-01-20	2024-12-05	선샤인 레이크 파르마 컴퍼니 리미티드	치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2021191875A1 (en)	2020-03-26	2021-09-30	Glaxosmithkline Intellectual Property Development Limited	Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3514450A1 (de) *	1985-04-22	1986-10-23	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von imidaten sowie neue arylsubstituierte imidate
GB9127376D0 (en) *	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
DE4310202A1 (de) *	1992-03-30	1993-10-07	Ciba Geigy	µ-Ketoimidoester als Stabilisatoren für chlorhaltige Polymerisate
FR2727111B1 (fr) *	1994-11-21	1997-01-17	Hoechst Lab	Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments

1995
- 1995-06-14 DE DE69529101T patent/DE69529101T2/de not_active Expired - Lifetime
- 1995-06-14 JP JP8501803A patent/JP2989010B2/ja not_active Expired - Lifetime
- 1995-06-14 AU AU28917/95A patent/AU692892B2/en not_active Ceased
- 1995-06-14 EP EP95924405A patent/EP0765308B1/en not_active Expired - Lifetime
- 1995-06-14 WO PCT/GB1995/001378 patent/WO1995034534A1/en not_active Ceased
- 1995-06-14 ES ES99116304T patent/ES2189322T3/es not_active Expired - Lifetime
- 1995-06-14 DK DK99116304T patent/DK0957087T3/da active
- 1995-06-14 CN CN95194518A patent/CN1070849C/zh not_active Expired - Fee Related
- 1995-06-14 BR BR9507995A patent/BR9507995A/pt not_active IP Right Cessation
- 1995-06-14 HU HU9603454A patent/HUT77407A/hu unknown
- 1995-06-14 PT PT95924405T patent/PT765308E/pt unknown
- 1995-06-14 SI SI9530412T patent/SI0765308T1/xx unknown
- 1995-06-14 KR KR1019960707192A patent/KR100430207B1/ko not_active Expired - Fee Related
- 1995-06-14 US US10/407,204 patent/USRE39576E1/en not_active Expired - Lifetime
- 1995-06-14 DK DK95924405T patent/DK0765308T3/da active
- 1995-06-14 ZA ZA954940A patent/ZA954940B/xx unknown
- 1995-06-14 PT PT99116304T patent/PT957087E/pt unknown
- 1995-06-14 US US08/750,679 patent/US5889056A/en not_active Ceased
- 1995-06-14 AT AT99116304T patent/ATE229001T1/de not_active IP Right Cessation
- 1995-06-14 SI SI9530645T patent/SI0957087T1/xx unknown
- 1995-06-14 EP EP99116304A patent/EP0957087B1/en not_active Expired - Lifetime
- 1995-06-14 ES ES95924405T patent/ES2145282T3/es not_active Expired - Lifetime
- 1995-06-14 NZ NZ289157A patent/NZ289157A/en not_active IP Right Cessation
- 1995-06-14 IL IL11414295A patent/IL114142A/xx not_active IP Right Cessation
- 1995-06-14 CA CA002192668A patent/CA2192668A1/en not_active Abandoned
- 1995-06-14 DE DE69516141T patent/DE69516141T2/de not_active Expired - Fee Related
- 1995-06-14 AT AT95924405T patent/ATE191470T1/de not_active IP Right Cessation
- 1995-06-14 RU RU97100747/04A patent/RU2162841C2/ru not_active IP Right Cessation
- 1995-06-15 MY MYPI95001621A patent/MY115437A/en unknown
- 1995-07-15 TW TW084107349A patent/TW442453B/zh not_active IP Right Cessation
1996
- 1996-11-13 IS IS4384A patent/IS4384A/is unknown
- 1996-12-05 MX MX9606136A patent/MX9606136A/es not_active IP Right Cessation
- 1996-12-13 NO NO965379A patent/NO308655B1/no unknown
- 1996-12-13 FI FI965019A patent/FI965019A7/fi not_active Application Discontinuation
1999
- 1999-02-25 IL IL12871799A patent/IL128717A0/xx not_active IP Right Cessation
- 1999-06-07 JP JP16019399A patent/JP3614711B2/ja not_active Expired - Fee Related
2000
- 2000-06-22 GR GR20000401441T patent/GR3033746T3/el not_active IP Right Cessation
2001
- 2001-09-07 CY CY0100026A patent/CY2238B1/xx unknown
2004
- 2004-06-03 CY CY0400042A patent/CY2455B1/xx unknown

Also Published As

Publication number	Publication date
EP0957087A2 (en)	1999-11-17
KR100430207B1 (ko)	2004-07-19
DE69516141T2 (de)	2000-10-19
PT957087E (pt)	2003-04-30
HU9603454D0 (en)	1997-02-28
NO308655B1 (no)	2000-10-09
DK0765308T3 (da)	2000-09-11
CN1155276A (zh)	1997-07-23
CA2192668A1 (en)	1995-12-21
ES2145282T3 (es)	2000-07-01
AU692892B2 (en)	1998-06-18
CY2455B1 (en)	2005-06-03
AU2891795A (en)	1996-01-05
DE69529101D1 (de)	2003-01-16
IL114142A (en)	2000-02-17
ES2189322T3 (es)	2003-07-01
WO1995034534A1 (en)	1995-12-21
NZ289157A (en)	1998-03-25
CY2238B1 (en)	2003-07-04
MY115437A (en)	2003-06-30
CN1070849C (zh)	2001-09-12
FI965019A0 (fi)	1996-12-13
NO965379L (no)	1996-12-13
ZA954940B (en)	1996-12-17
SI0765308T1 (sl)	2000-08-31
FI965019A7 (fi)	1996-12-13
JP2000026402A (ja)	2000-01-25
PT765308E (pt)	2000-09-29
SI0957087T1 (en)	2003-04-30
DE69529101T2 (de)	2003-11-13
IL128717A0 (en)	2000-01-31
JP3614711B2 (ja)	2005-01-26
US5889056A (en)	1999-03-30
ATE229001T1 (de)	2002-12-15
HUT77407A (hu)	1998-04-28
ATE191470T1 (de)	2000-04-15
GR3033746T3 (en)	2000-10-31
HK1003935A1 (en)	1998-11-13
EP0765308B1 (en)	2000-04-05
MX9606136A (es)	1998-06-30
TW442453B (en)	2001-06-23
JPH10506371A (ja)	1998-06-23
NO965379D0 (no)	1996-12-13
EP0957087A3 (en)	2000-12-20
IL114142A0 (en)	1995-10-31
JP2989010B2 (ja)	1999-12-13
DK0957087T3 (da)	2003-03-24
EP0765308A1 (en)	1997-04-02
RU2162841C2 (ru)	2001-02-10
BR9507995A (pt)	1997-08-05
EP0957087B1 (en)	2002-12-04
DE69516141D1 (de)	2000-05-11
USRE39576E1 (en)	2007-04-17

Publication	Publication Date	Title
IS4384A (is)	1996-11-13	Ensím latar
WO2003006425A3 (en)	2003-11-27	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
GR3030167T3 (en)	1999-08-31	Amidino derivatives useful as nitric oxide synthase inhibitors
IL135536A0 (en)	2001-05-20	Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
AU6645998A (en)	1998-07-17	Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
ATE269312T1 (de)	2004-07-15	N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
DE69705829D1 (de)	2001-08-30	Meta-substituierte phenylsulphonamidderivate
DK0471236T3 (da)	1995-07-24	Imidazopyridinderivater og deres anvendelse
DE69413274D1 (de)	1998-10-22	Chinoloncarbonsäurederivate, ihre Herstellung und ihre Verwendung als Zelladhäsion Inhibitoren
DK0824588T3 (da)	2004-08-16	Inhibitor af IL-6 aktivitet
DE60228316D1 (en)	2008-09-25	Xanthinoxidaseinhibitoren
BG101655A (bg)	1998-09-30	Състав за защита на посеви
NO940245D0 (no)	1994-01-24	Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
EA200000204A1 (ru)	2000-10-30	Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DZ1724A1 (fr)	2002-02-17	Nouvelles azétidinones substituées comme agents anti-inflammatoires et anti-dégénérescence.
BG103520A (en)	2000-06-30	The use of aminothiazoles as microbicides
PT1423385E (pt)	2008-09-24	Intermediários para preparar conjugados inibidores da neuraminidase
PT971714E (pt)	2002-12-31	Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
EP1007511A4 (en)	2001-07-11	PRODUCTION OF BETA MEHTYLCARBAPENEM INTERMEDIATE PRODUCTS